RETRACTED: Cilostazol protects mice against myocardium ischemic/reperfusion injury by activating a PPARγ/JAK2/STAT3 pathway
- 1 October 2017
- journal article
- retracted article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 94, 995-1001
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Anti-inflammatory Effect of Protocatechuic Aldehyde on Myocardial Ischemia/Reperfusion Injury In Vivo and In VitroInflammation, 2012
- Luteolin Limits Infarct Size and Improves Cardiac Function after Myocardium Ischemia/Reperfusion Injury in Diabetic RatsPLOS ONE, 2012
- Role of Melatonin in Preventing Mitochondrial Dysfunction in Myocardial Ischemia-Reperfusion InjuryThe American Journal of Cardiology, 2010
- PPARs and the Cardiovascular SystemAntioxidants & Redox Signaling, 2009
- Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusionBasic Research in Cardiology, 2008
- RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine modelAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Myocardial Reperfusion InjuryNew England Journal of Medicine, 2007
- COMPARISON OF THE PROTECTIVE EFFECTS OF TYPE III PHOSPHODIESTERASE (PDE3) INHIBITOR (CILOSTAZOL) AND ACETYLSALICYLIC ACID ON INTESTINAL MICROCIRCULATION AFTER ISCHEMIA REPERFUSION INJURY IN MICEShock, 2006
- Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial StenosisStroke, 2005
- Does reperfusion injury exist in humans?JACC, 1993